SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Granules India surges on completing expansion at Gagillapur facility

26 Apr 2013 Evaluate

Granules India is currently trading at Rs. 114.80, up by 2.55 points or 2.27% from its previous closing of Rs. 112.25 on the BSE.

The scrip opened at Rs. 112.05 and has touched a high and low of Rs. 117.00 and Rs. 111.80 respectively. So far 14,568 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 234.50 on 11-Sep-2012 and a 52 week low of Rs. 85.65 on 15-May-2012.

Last one week high and low of the scrip stood at Rs. 116.00 and Rs. 100.25 respectively. The current market cap of the company is Rs. 231 crore.

The promoters holding in the company stood at 44.44%, while Institutions and Non-Institutions held 1.57% and 53.89% respectively.

Granules India has completed the expansion at its Gagillapur facility in Andhra Pradesh. The company has commenced operations of the new capacity and expects to scale up operations over the next several months. Due to the delay in the scale-up of the new capacity, margins slipped since the company incurred costs to run the new facility without a concurrent increase in production. The company expects margins to increase since production is increasing at the facility.

The company’s consolidated net sales for fiscal year ended March 31, 2013 increased 17% to Rs 764 crore, while consolidated net profit increased 9% to Rs 33 crore.

Granules India is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.

Granules India Share Price

661.30 -2.45 (-0.37%)
21-Apr-2026 09:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1677.90
Dr. Reddys Lab 1230.00
Cipla 1229.00
Zydus Lifesciences 932.15
Lupin 2333.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×